---

---

entities : Sanofi   

save search

---

Global Fibrate Drugs Market Report 2024: A $5.14 Billion Market by 2034, Rising from S2.95 Billion in 2023
Published: 2024-03-11 (Crawled : 17:00) - prnewswire.com
ABT | $109.21 0.29% 0.34% 7.3M |

Health Technology

| -9.85% | O: 0.26% H: 0.0% C: 0.0%
SNY | $45.81 -0.93% -0.94% 1.4M |

Health Technology

| -2.48% | O: 0.57% H: 0.0% C: 0.0%
report global market

---

Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
Published: 2024-03-11 (Crawled : 17:00) - biospace.com/
SNY | $45.81 -0.93% -0.94% 1.4M |

Health Technology

| -2.48% | O: 0.57% H: 0.0% C: 0.0%

---

FDA Decisions: Wegovy Approved for CV Indication; Viatris and Mapi’s MS Drug ...
Published: 2024-03-11 (Crawled : 17:00) - biospace.com/
PRGO A | $29.96 -0.56% 0.0% 1.4M |

Health Technology

| -0.4% | O: 0.0% H: 2.38% C: 1.12%
JNJ | $144.45 -2.13% 0.03% 13M |

Health Technology

| -7.14% | O: 0.43% H: 0.0% C: 0.0%
ABT | $109.21 0.29% 0.34% 7.3M |

Health Technology

| -9.85% | O: 0.26% H: 0.0% C: 0.0%
SNY | $45.81 -0.93% -0.94% 1.4M |

Health Technology

| -2.48% | O: 0.57% H: 0.0% C: 0.0%
fda drug wegovy approved

---

Incyte Gets Phase II Win, Targets Blockbuster Dupixent in Skin Disease
Published: 2024-03-11 (Crawled : 16:00) - biospace.com/
SNY | $45.81 -0.93% -0.94% 1.4M |

Health Technology

| -2.48% | O: 0.57% H: 0.0% C: 0.0%
disease dupixent skin

---

Vaccine research market size to grow at a CAGR of 9.88% from 2022 to 2027, Abbott Laboratories, Astellas Pharma Inc., AstraZeneca Plc, more to emerge as key players, Technavio
Published: 2024-03-11 (Crawled : 14:30) - prnewswire.com
CMXHF | $180.75 -19.21% 33 |

n/a

| -2.3% | O: 0.41% H: 0.0% C: 0.0%
CSLLY | $89.5 3.3% 44K |

n/a

| -5.03% | O: -4.92% H: 3.76% C: 3.44%
GLAXF | $20.2 -14.18% 510 |

Health Technology

| -5.92% | O: -3.4% H: 1.49% C: 1.49%
AZNCF | $135.94 -4.19% 770 |

Health Technology

| 3.67% | O: 1.55% H: 0.82% C: 0.16%
ALPMY | $9.2715 -1.11% 500K |

Manufacturing

| -12.7% | O: -1.41% H: 5.06% C: 4.01%
GSK | $39.95 -1.36% 0.0% 2.4M |

Health Technology

| -6.12% | O: -0.6% H: 0.19% C: 0.09%
ABT | $109.21 0.29% 0.34% 7.3M |

Health Technology

| -9.85% | O: 0.26% H: 0.0% C: 0.0%
SNY | $45.81 -0.93% -0.94% 1.4M |

Health Technology

| -2.48% | O: 0.57% H: 0.0% C: 0.0%
AZN | $68.27 -0.67% -0.67% 3.8M |

Health Technology

| 3.35% | O: 1.08% H: 0.82% C: 0.67%
pharma vaccine astrazeneca research key market

---

FDA Decisions: Wegovy Approved for CV Indication; Viatris and Mapi’s MS Drug Rejected
Published: 2024-03-11 (Crawled : 14:30) - biospace.com/
PRGO A | $29.96 -0.56% 0.0% 1.4M |

Health Technology

| -0.4% | O: 0.0% H: 2.38% C: 1.12%
JNJ | $144.45 -2.13% 0.03% 13M |

Health Technology

| -7.14% | O: 0.43% H: 0.0% C: 0.0%
ABT | $109.21 0.29% 0.34% 7.3M |

Health Technology

| -9.85% | O: 0.26% H: 0.0% C: 0.0%
SNY | $45.81 -0.93% -0.94% 1.4M |

Health Technology

| -2.48% | O: 0.57% H: 0.0% C: 0.0%
fda drug wegovy approved

---

FDA Rejects Viatris, Mapi’s Long-Acting Multiple Sclerosis Injection
Published: 2024-03-11 (Crawled : 14:00) - biospace.com/
SNY | $45.81 -0.93% -0.94% 1.4M |

Health Technology

| -2.48% | O: 0.57% H: 0.0% C: 0.0%
fda sclerosis injection

---

Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
SNY | $45.81 -0.93% -0.94% 1.4M |

Health Technology

| -2.48% | O: 0.57% H: 0.0% C: 0.0%
REGN | $894.265 -0.48% -0.48% 610K |

Health Technology

| -7.25% | O: 0.23% H: 0.9% C: -0.68%
praluent fda children genetic cholesterol approval treat injection

---

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
SNY | $45.81 -0.93% -0.94% 1.4M |

Health Technology

| -2.48% | O: 0.57% H: 0.0% C: 0.0%
FGEN | $1.29 -1.53% -1.55% 860K |

Health Technology

| -27.22% | O: -1.67% H: 3.95% C: -3.39%
medical

---

Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
Published: 2024-03-11 (Crawled : 06:00) - globenewswire.com
SNY | $45.81 -0.93% -0.94% 1.4M |

Health Technology

| -2.48% | O: 0.57% H: 0.0% C: 0.0%
dermatitis response potential results

---

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
Published: 2024-03-10 (Crawled : 16:20) - globenewswire.com
SNY | $45.81 -0.93% -0.94% 1.4M |

Health Technology

| Email alert Add to watchlist
MLTX | $43.61 -0.07% -0.07% 280K |

| Email alert Add to watchlist
SNYNF | $92.966 -2.18% 630 |

Health Technology

| Email alert Add to watchlist
nanobody day active

---

US Healthcare Advertising Market Analysis Report 2024-2032: A $23.5 Billion Industry in 2023 with Insights on Major Players' Sales and Advertising Spend
Published: 2024-03-09 (Crawled : 04:20) - prnewswire.com
SNY | $45.81 -0.93% -0.94% 1.4M |

Health Technology

| Email alert Add to watchlist
LLY | $746.74 -0.54% 1.01% 2.5M |

Health Technology

| Email alert Add to watchlist
GLAXF | $20.2 -14.18% 510 |

Health Technology

| Email alert Add to watchlist
AZNCF | $135.94 -4.19% 770 |

Health Technology

| Email alert Add to watchlist
SNYNF | $92.966 -2.18% 630 |

Health Technology

| Email alert Add to watchlist
AZN | $68.27 -0.67% -0.67% 3.8M |

Health Technology

| Email alert Add to watchlist
JNJ | $144.45 -2.13% 0.03% 13M |

Health Technology

| Email alert Add to watchlist
GSK | $39.95 -1.36% 0.0% 2.4M |

Health Technology

| Email alert Add to watchlist
sales report market

---

Global Dyslipidemia Drugs Market Set to Reach $30.98 Billion by 2034 with Statins Dominating and PCSK9 Inhibitors Showing Rapid Growth
Published: 2024-03-08 (Crawled : 18:00) - prnewswire.com
AZNCF | $135.94 -4.19% 770 |

Health Technology

| 5.18% | O: 3.21% H: 0.0% C: -1.71%
JNJ | $144.45 -2.13% 0.03% 13M |

Health Technology

| -7.77% | O: -0.68% H: 0.0% C: 0.0%
SNY | $45.81 -0.93% -0.94% 1.4M |

Health Technology

| -2.56% | O: -0.08% H: 0.0% C: 0.0%
AZN | $68.27 -0.67% -0.67% 3.8M |

Health Technology

| 3.84% | O: -0.03% H: 0.62% C: 0.5%
rapid reach global set growth market

---

FDA Decisions: BeiGene Secures Record Fifth Oncology Approval for Brukinsa
Published: 2024-03-08 (Crawled : 18:00) - biospace.com/
PRGO A | $29.96 -0.56% 0.0% 1.4M |

Health Technology

| 1.48% | O: 0.98% H: 3.17% C: 0.9%
JNJ | $144.45 -2.13% 0.03% 13M |

Health Technology

| -7.77% | O: -0.68% H: 0.0% C: 0.0%
ABT | $109.21 0.29% 0.34% 7.3M |

Health Technology

| -9.33% | O: 0.58% H: 0.0% C: 0.0%
SNY | $45.81 -0.93% -0.94% 1.4M |

Health Technology

| -2.56% | O: -0.08% H: 0.0% C: 0.0%
fda brukinsa approval

---

FDA Decisions: BeiGene Secures Record Fifth Oncology Approval for Brukinsa; Opdivo Approved for B...
Published: 2024-03-08 (Crawled : 17:00) - biospace.com/
PRGO A | $29.96 -0.56% 0.0% 1.4M |

Health Technology

| 1.48% | O: 0.98% H: 3.17% C: 0.9%
JNJ | $144.45 -2.13% 0.03% 13M |

Health Technology

| -7.77% | O: -0.68% H: 0.0% C: 0.0%
ABT | $109.21 0.29% 0.34% 7.3M |

Health Technology

| -9.33% | O: 0.58% H: 0.0% C: 0.0%
SNY | $45.81 -0.93% -0.94% 1.4M |

Health Technology

| -2.56% | O: -0.08% H: 0.0% C: 0.0%
fda opdivo approved approval

---

AstraZeneca, Sanofi’s Beyfortus 90% Effective at Preventing RSV Hospitalizations: CDC
Published: 2024-03-08 (Crawled : 15:30) - biospace.com/
SNY | $45.81 -0.93% -0.94% 1.4M |

Health Technology

| -2.56% | O: -0.08% H: 0.0% C: 0.0%
beyfortus rsv

---

Biopharma Layoff Tracker 2024: Kronos Bio, Sumitomo, Evonik and More Cut Staff
Published: 2024-03-08 (Crawled : 15:30) - biospace.com/
RLYB | $1.81 -1.09% -1.1% 740K |

| -1.61% | O: 0.54% H: 5.88% C: 0.0%
JNJ | $144.45 -2.13% 0.03% 13M |

Health Technology

| -7.77% | O: -0.68% H: 0.0% C: 0.0%
VXRT | $0.8903 -2.07% -2.11% 1.3M |

Health Technology

| -18.1% | O: 0.0% H: 9.46% C: 7.21%
TXMD | $1.91 -2.05% -2.09% 46K |

Health Technology

| -14.85% | O: 3.06% H: 3.39% C: -1.27%
SNY | $45.81 -0.93% -0.94% 1.4M |

Health Technology

| -2.56% | O: -0.08% H: 0.0% C: 0.0%
PTCT | $25.28 -1.56% -1.58% 710K |

Health Technology

| -16.51% | O: 1.89% H: 0.99% C: -0.57%
NKTR | $1.5 -4.46% -4.67% 1.6M |

Health Technology

| 64.29% | O: -1.08% H: 5.79% C: -3.83%
MOR | $17.91 -0.61% -0.61% 560K |

Health Technology

| 0.95% | O: 0.17% H: 0.34% C: 0.17%
GLPG | $29.5 -1.01% -1.02% 260K |

Health Technology

| -13.52% | O: 0.35% H: 1.39% C: -0.32%
AMRN | $0.897 -2.35% -2.41% 810K |

Health Technology

| -0.91% | O: -0.38% H: 4.17% C: -0.04%
GOOGL | $154.4 -0.3% -0.3% 21M |

Technology Services

| 15.24% | O: -0.13% H: 2.89% C: 0.89%
GOOG | $155.98 -0.22% -0.22% 15M |

Technology Services

| 15.59% | O: -0.15% H: 2.93% C: 0.93%
OCX | $2.66 5.14% 4.89% 170K |

Health Technology

| -15.67% | O: -3.0% H: 5.33% C: 3.09%
biopharma

---

EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
Published: 2024-03-08 (Crawled : 12:00) - globenewswire.com
SNY | $45.81 -0.93% -0.94% 1.4M |

Health Technology

| -2.56% | O: -0.08% H: 0.0% C: 0.0%
REGN | $894.265 -0.48% -0.48% 610K |

Health Technology

| -7.68% | O: 0.0% H: 0.27% C: -0.46%
eylea lancet macular injection diabetic

---

Net Zero Strategies in the Media Sector: 2024 Thematic Research Report - 15/20 Companies Analyzed have Set Either a Short or Long-term Target to Reduce their Emissions
Published: 2024-03-08 (Crawled : 10:00) - prnewswire.com
SNY | $45.81 -0.93% -0.94% 1.4M |

Health Technology

| -2.56% | O: -0.08% H: 0.0% C: 0.0%
FOXA | $30.42 0.23% 0.23% 3.1M |

Consumer Services

| 5.9% | O: 0.17% H: 0.98% C: 0.52%
FOX | $27.95 0.11% 0.11% 1.2M |

Consumer Services

| 6.93% | O: 0.19% H: 0.99% C: 0.61%
media companies report research set

---

Global Artemisinin Market Report 2024, Featuring Profiles of Top Players Including Sanofi, Artemis, KPC Pharmaceuticals, Guilin Pharmaceutical, KERUI, Phytomedics, AIFLINC, Alchem and Sanmark
Published: 2024-03-08 (Crawled : 05:00) - prnewswire.com
SNY | $45.81 -0.93% -0.94% 1.4M |

Health Technology

| -2.56% | O: -0.08% H: 0.0% C: 0.0%
report global market

---

Gainers vs Losers

58%

42%

Top 10 Gainers

WISA 4 | $6.06 246.29% 71.12% 200M |

Electronic Technology

VIAO | $0.265 -13.96% 35.85% 960K |

Electronic Technology

JAGX | $0.178 49.83% 33.26% 600M |

Health Technology

SXTC | $1.68 43.59% 30.36% 34M |

Health Technology

DYNT | $0.531 43.36% 30.24% 22M |

Health Technology

KA | $0.4796 41.06% 29.11% 5.3M |

Manufacturing

PALI | $5.86 40.87% 29.01% 29M |

Manufacturing

CLNN | $0.319 -3.74% 28.75% 6.3M |

BSGM | $1.52 38.18% 27.63% 3.3M |

Health Technology

MCBC | $13.67 37.66% 27.36% 2.2M |

Finance

---

Your saved searches

---